Literature DB >> 8610

Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover.

S R Snider, C Hutt, B Stein, A L Prasad, S Fahn.   

Abstract

The dopamine agonist, bromocriptine, produced either inhibition or stimulation of motor behaviour in rats depending upon the dose and time after administration. Stimulation of motor activity occurred only with high doses after a 1-2 h delay. Both inhibition and stimulation were associated with decreased turnover of dopamine in the brain. Release of noradrenaline in brain and noradrenaline plus adrenaline in adrenal varied with motor activity. It is suggested that low doses of bromocriptine inhibit behaviour by activating an inhibitory presynaptic receptor, resulting in reduced synthesis and release of dopamine, whilst high doses cause behavioural excitation by activating the post-synaptic dopamine receptor.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 8610     DOI: 10.1111/j.2042-7158.1976.tb02796.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  16 in total

1.  Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats.

Authors:  R Pagliari; L Peyrin; O Crambes
Journal:  J Neural Transm Gen Sect       Date:  1995

2.  Is dopamine a neurohormone of the adrenal medulla? Studies with morphine stimulation.

Authors:  S R Snider; C Miller; A L Prasad; V Jackson; S Fahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-03       Impact factor: 3.000

3.  Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study.

Authors:  D M Jackson; S B Ross; L G Larsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

4.  Dopamine D2 agonist-induced behavioural depression is reversed by dopamine D1 agonists.

Authors:  D M Jackson; S B Ross; S R Edwards
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

5.  Differential behavioral and biochemical effects of four dopaminergic agonists.

Authors:  G Gianutsos; K E Moore
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

Review 6.  Hypothesis: bromocriptine lacks intrinsic dopamine receptor stimulating properties.

Authors:  D M Jackson; O F Jenkins
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

7.  Effect of bromocriptine administration on gastric acid and gastrin secretion in man.

Authors:  R Caldara; C Ferrari; M Romussi; A Paracchi
Journal:  J Endocrinol Invest       Date:  1979 Jan-Mar       Impact factor: 4.256

8.  Involvement of the adrenal glands in the hypotensive response to bromocriptine in spontaneously hypertensive rats.

Authors:  T C Hamilton
Journal:  Br J Pharmacol       Date:  1981-03       Impact factor: 8.739

9.  Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.

Authors:  P Price; A Debono; J D Parkes; C D Marsden; J Rosenthaler
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

10.  Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy.

Authors:  H Y Meltzer; T Kolakowska; A Robertson; B J Tricou
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.